ArticleCJC open2025
Long-Term Outcomes After Mitral Valve Replacement in Sex- and Age-Matched Patients With vs Without Mitral Annular Calcification.
Article in CJC open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of mitral annular calcification in mitral valve surgery: 25-year Mayo Clinic experience.Annals of cardiothoracic surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mitral annular calcification (MAC) portends the need for a technically challenging mitral valve surgery and is associated with poor outcomes after mitral valve replacement (MVR). No study has compared long-term outcomes for patients with vs without MAC in age- and sex-matched cohorts. Methods: Between 2000 and 2017, a total of 67 patients with MAC who underwent MVR were age- and sex-matched 1:3 with patients with other etiologies without MAC to create a study cohort of 268. An extended Cox regression model was used to investigate long-term outcomes of patients with MAC, compared to those with other mitral etiologies. Results: The groups were matched for age (MAC, 70.5 years; non-MAC, 70.4 years) and sex (MAC, 61.2% male; non-MAC, 61.7% male). MAC was not a risk factor for 1-year mortality. After 1 year, MAC was an independent risk factor for reduced survival (hazard ratio 2.781, 95% confidence interval 1.642-4.709, Conclusions: In an age- and sex-matched cohort, patients with MAC have similar early outcomes, but poorer long-term survival following MVR, compared to those without MAC, suggesting that MVR can be performed safely in selected patients with MAC. MAC and PVD are independent risk factors for reduced long-term survival.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.